NCT00513279

To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334

A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

GSK618334 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will evaluate the safety, tolerability and pharmacokinetics of single doses of GSK618334 in healthy volunteers.

Conditions

• Substance Dependence

Interventions

Type	Name	Description
DRUG	GSK618334	GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
DRUG	GSK618334 matching placebo tablets	GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.

Timeline

• Start date: 2007-06-28
• Primary completion: 2007-10-04
• Completion: 2007-10-04
• First posted: 2007-08-08
• Last updated: 2017-09-15

Locations

1 site across 1 country: United Kingdom